Guo Wenjing, Pan Ling, Yang Ruiyu, Sun Jiali, Hu Qinglin, Huang Pingping
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Tianjin Institutes of Health Science, Tianjin, China.
Blood Sci. 2024 Jan 15;6(1):e00175. doi: 10.1097/BS9.0000000000000175. eCollection 2024 Jan.
Numerous studies have discussed the therapeutic outcomes of using cell therapy or acupuncture to treat peripheral artery disease (PAD). However, there are no long-term studies on the safety and efficacy of transplanting peripheral blood mononuclear cells (PBMNCs) via acupoints to treat PAD. We first reviewed the short-term and long-term clinical results of PAD patients treated with PBMNCs through intramuscular non-acupoint transplantation (control group; n = 45) or intramuscular acupoint transplantation (acupoint group; n = 45) at a single university hospital general medical center between December 2002 and September 2022. Pain intensity (assessed with the verbal rating scale [VRS] score) in the acupoint group was considerably lower than that in the control group at month 1 (mean ± standard deviation [SD]: 1.29 ± 0.96 vs 1.76 ± 0.82; = 0.016) and month 3 (mean ± SD: 1.27 ± 0.90 vs 1.61 ± 0.86; = 0.042). We observed significant improvement of VRS score ( < .001 for all) and ankle-brachial index (ABI; < .001 for all) from baseline in both groups at months 1, 3, 6, 12, 36, and 60. The 10-year cumulative rate of major amputation-free survival (MAFS) was higher in the acupoint group as compared to the control group (81.9%, 95% confidence interval [CI]: 71.3%-94.1% vs 78.5%, 95% CI: 66.7%-92.3%; = 0.768). Compared with the routine injection method, intramuscular transplantation of PBMNCs via selected acupoints could significantly decrease the short-term pain intensity in patients with PAD, which remains an option for consideration.
众多研究探讨了使用细胞疗法或针灸治疗外周动脉疾病（PAD）的治疗效果。然而，关于通过穴位移植外周血单个核细胞（PBMNCs）治疗PAD的安全性和有效性，尚无长期研究。我们首先回顾了2002年12月至2022年9月期间，在一所大学医院综合医疗中心，接受肌肉非穴位移植（对照组；n = 45）或肌肉穴位移植（穴位组；n = 45）PBMNCs治疗的PAD患者的短期和长期临床结果。穴位组在第1个月（平均值±标准差[SD]：1.29±0.96 vs 1.76±0.82；P = 0.016）和第3个月（平均值±SD：1.27±0.90 vs 1.61±0.86；P = 0.042）时的疼痛强度（用视觉模拟评分法[VRS]评分评估）显著低于对照组。在第1、3、6、12、36和60个月时，两组的VRS评分（所有P均<0.001）和踝肱指数（ABI；所有P均<0.001）较基线均有显著改善。穴位组的10年主要无截肢生存率（MAFS）累积率高于对照组（81.9%，95%置信区间[CI]：71.3%-94.1% vs 78.5%，95%CI：66.7%-92.3%；P = 0.768）。与常规注射方法相比，通过选定穴位进行PBMNCs的肌肉移植可显著降低PAD患者的短期疼痛强度，这仍是一个可供考虑的选择。
